Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC

ClinicalTrials.gov ID: NCT00602030

Public ClinicalTrials.gov record NCT00602030. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study With a Lead in Phase of Erlotinib With or Without SNDX-275 in Patients With NSCLC After Failure In Up to Two Prior Chemotherapeutic Regimens for Advanced Disease

Study identification

NCT ID
NCT00602030
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Syndax Pharmaceuticals
Industry
Enrollment
141 participants

Conditions and interventions

Interventions

  • Entinostat Drug
  • Placebo Drug
  • Erlotinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 7, 2008
Primary completion
Feb 3, 2010
Completion
Jan 31, 2012
Last update posted
Aug 21, 2022

2008 – 2012

United States locations

U.S. sites
30
U.S. states
13
U.S. cities
29
Facility City State ZIP Site status
HOPE (Hematology Oncology Physicians & Extenders) Tucson Arizona
Rocky Mountain Cancer Center Denver Colorado
Advanced Medical Specialties Miami Florida
Ocala Oncology Center Ocala Florida
Cancer Centers of Florida Ocoee Florida
Hematology Oncology Associates of Illinois Chicago Illinois
Central Indiana Cancer Centers Indianapolis Indiana
Kansas City Cancer Centers Overland Park Kansas
Alliance Hematology Oncology Westminster Maryland
St Joseph Oncology Saint Joseph Missouri
The Center for Cancer Care & Research St Louis Missouri
Mahonig Valley Hematology Oncology Associates Boardman Ohio
Dayton Oncology & Hematology Kettering Ohio
Oncology Associates of Oregon Eugene Oregon
Texas Oncology Amarillo Texas
Texas Oncology Austin Texas
Texas Oncology Bedford Texas
Texas Oncology, Sammons Cancer Center Dallas Texas
Texas Oncology Dallas Texas
Texas Oncology Fort Worth Texas
Texas Oncology Garland Texas
Texas Oncology Longview Texas
Texas Oncology Midland Texas
Texas Oncology Odessa Texas
Texas Oncology Tyler Texas
Fairfax Northern Virginia Hematology-Oncology Fairfax Virginia
Virginia Oncology Associates Norfolk Virginia
Highline Medical Oncology Burien Washington
Cancer Care Northwest Spokane Washington
Yakima Valley Memorial Hospital/North Star Lodge Yakima Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00602030, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 21, 2022 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00602030 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →